The report, State of Disarray: How States’ Inability to Oversee Compounding Pharmacies Puts Public Health at Risk, resulted from a letter sent by Reps. Markey, Henry Waxman (D-CA), John Dingell (D-MI), Frank Pallone Jr. (D-NJ), and Diana DeGette (D-CO) to boards of pharmacy in all states, territories, and Washington, DC, requesting answers to six questions. All boards of pharmacy—except Rhode Island, Guam, Puerto Rico, and the U.S. Virgin Islands—responded to the letter.
These Members of Congress are Democratic members of the House Energy & Commerce Committee, and all but Pallone are members of its Subcommittee on Oversight and Investigations (with Dingell as a nonvoting member). Markey’s report came before today’s House Energy & Commerce Subcommittee on Oversight and Investigations hearing, with FDA Commissioner Margaret A. Hamburg as the only scheduled witness.
“Deficiencies associated with state record-keeping, communication, resources, and specialized expertise combined with the inability of any single state to monitor the adequacy of compounding pharmacy safety in 49 other states appear to be systemic barriers to relying solely on the states to assure the safety of compounded drug products,” according to the report. “The FDA needs clear, unambiguous authority that would enable it to set and enforce safety standards for the riskiest and largest compounding pharmacies, as well as those that sell compounded drugs across state lines.”
Continue reading here